| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $243K | -22.4% | -62.1% |
| SG&A Expense | $1.1M | -43.9% | -25.7% |
| Operating Income | -$1.3M | +40.9% | -241.1% |
| Net Income | -$1.7M | +44.5% | -394.5% |
| EPS (Basic) | -$0.63 | -1160.0% | +80.7% |
| EPS (Diluted) | -$0.63 | -1160.0% | +80.7% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Accounts Receivable | $271K | -20.8% | — |
| Current Assets | $1.2M | -60.1% | -21.5% |
| Total Assets | $1.7M | -51.1% | -78.3% |
| Current Liabilities | $17.3M | -15.3% | +91.3% |
| Stockholders' Equity | -$16.1M | +7.7% | +9.4% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.4M | — | — |
| Investing Cash Flow | $26K | — | — |
| Financing Cash Flow | $2.7M | — | — |